Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Jaap

Jaap Bruinink, Eindhoven NL

Patent application numberDescriptionPublished
20080211734Combined Single/Multiple View-Display - The present invention relates to a display device comprising an outer display stacked with an inner display and being arranged to be operable in a first, multiple view mode and a second, single view mode. An idea of the invention is to arrange an electrophoretic display on top of an emissive display. The display device may be operated in two modes; a first mode being a multiple or dual view mode and a second mode being a single view mode. In order to activate the single view mode, the outer display is set in a transparent state and the inner display is turned on, such that it displays desired objects. In the multiple view mode, the outer display is functioning as a 3D-barrier. Hence, some of the picture elements of the outer display are set in a transparent state while others are set in an opaque state. The viewer sees a different picture with each respective eye, and will accordingly experience a multiple view picture of an object that is displayed on the inner display.09-04-2008

Jaap De Slegte, Doetinchem NL

Patent application numberDescriptionPublished
20100069322INHIBITION OF CHOLERA TOXINS BY GALATOOLIGOSACCHARIDES (GOS) - The invention relates to nutritional and pharmaceutical compositions comprising non-digestible galactooligosaccharides (GOS) and uses thereof. In particular, it relates to the use of GOS species in preventing or treating disease caused by bacterial toxins. Provided is the use of GOS having a polymerization degree of 5 or higher, preferably 6 or higher, for the manufacture of a nutritional or pharmaceutical composition for the treatment or prevention of an acute or chronic disease associated with or caused by the adhesion and/or uptake of a cholera toxin family member. Also provided is a method for providing a GOS fraction capable of inhibiting cholera toxin (Ctx) binding to GM1 and fractions obtainable thereby.03-18-2010

Jaap Goudsmit, Amsterdam NL

Patent application numberDescriptionPublished
20080206279VACCINES AGAINST WEST NILE VIRUS - The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced. 08-28-2008
20090017068Vaccines against West Nile Virus - Described are vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.01-15-2009
20090285879Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from 11-19-2009
20100172917Binding molecules against SARS-coronavirus and uses thereof - Described are binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV, and can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from SAR.07-08-2010

Patent applications by Jaap Goudsmit, Amsterdam NL

Jaap Ruigrok, Eindhoven NL

Patent application numberDescriptionPublished
20080198473Variable Focus Lens - The invention relates to variable focus lenses based on magneto wetting and related devices, wherein two fluids, one of which is magnetically susceptible, are in contact over a meniscus. The shape of the meniscus is controlled by means of an applied magnetic field gradient. The contact angle between the chamber wall and the meniscus is a conserved. Implementation of special shaping to the internal or external walls of the chamber, while conserving the contact angle, results in better lens shape in the variable focus lens and lower levels of lens distortion.08-21-2008
20100001723BRIDGE TYPE SENSOR WITH TUNABLE CHARACTERISTIC - A bridge type magnetic sensor is disclosed having four resistive elements in a bridge arrangement, two of the resistive elements on opposing sides of the bridge having a magnetoresistive characteristic such that their resistance increases with increasing positive magnetic field and with increasing negative magnetic field. A frequency doubling is obtained because the output characteristic of the magnetic sensor is a V-shaped curve, where the signal rises for increasing positive and negative fields.01-07-2010
20100244189INTEGRATION SUBSTRATE WITH A ULTRA-HIGH-DENSITY CAPACITOR AND A THROUGH-SUBSTRATE VIA - An integration substrate for a system in package comprises a through-substrate via and a trench capacitor wherein with a trench filling that includes at least four electrically conductive capacitor-electrode layers in an alternating arrangement with dielectric layers. —The capacitor-electrode layers are alternatingly connected to a respective one of two capacitor terminals provided on the first or second substrate side. The trench capacitor and the through-substrate via are formed in respective trench openings and via openings in the semiconductor substrate, which have an equal lateral extension exceeding 10 micrometer. This structure allows, among other advantages, a particularly cost-effective fabrication of the integration substrate because the via openings and the trench openings in the substrate can be fabricated simultaneously.09-30-2010

Jaap Twisk, Amsterdam NL

Patent application numberDescriptionPublished
20110262399PORPHOBILINOGEN DEAMINASE GENE THERAPY - The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.10-27-2011

Jaap Van Der Louw, Oss NL

Patent application numberDescriptionPublished
20090291929STEROIDS HAVING A MIXED ANDROGENIC AND PROGESTAGENIC PROFILE - The invention provides for compounds having formula (1) wherein; R11-26-2009
20110009428NOVEL ANDROGENS - The compounds of the subject invention have a structure according to formula I:01-13-2011
20110065768NON-STEROIDAL ANDROGENS COMPOUNDS - This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula03-17-2011

Patent applications by Jaap Van Der Louw, Oss NL